

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Guardian Pharmacy of Indianapolis Nuclear, LLC d/b/a Radiopharmacy of Indianapolis, LLC</p> <p>2. 6538 Corporate Dr. Indianapolis, IN 46278</p>	<p>In accordance with letter dated April 19, 2024,</p>	<p>4. Expiration Date: July 31, 2027</p>
	<p>3. License No.: 13-32637-01MD is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-37428 Reference No.:</p>

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material between Atomic Nos. 3 and 83 with exceptions	A. Any	A. No single radionuclide to exceed 800 millicuries; 800 millicuries total	A. For preparation and distribution of radioactive drugs, including compounding of Iodine-131 and redistribution of unused molybdenum-99/technetium-99m generators to authorized recipients, in accordance with 10 CFR 32.72.
B. Molybdenum-99	B. Any	B. 250 curies total	B. Same as Item No. 9.A.
C. Technetium-99m	C. Any	C. 250 curies total	C. Same as Item No. 9.A.
D. Xenon-133	D. Any	D. 1.1 curies total	D. Same as Item No. 9.A.
E. Iodine-131	E. Any	E. 2.7 curies total	E. Same as Item No. 9.A.


**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.:
13-32637-01MD

Docket or Reference No.:
030-37428

Amendment No. 19

- | | | | |
|---|----------------------------------|--|--|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license | 9. Authorized use |
| F. Any byproduct material permitted by 10 CFR 35.65 | F. Sealed Sources | F. 75 millicuries total | F. For use in calibration and checking of the licensee's instruments. For redistribution of sealed sources initially distributed by a manufacturer licensed in accordance with 10 CFR 32.74 to authorized recipients for medical use and for non-medical use to authorized recipients. |
| G. Uranium - depleted in Uranium-235 | G. Metal | G. 600 kilograms total | G. For shielding for molybdenum-99/technetium-99m generators. |
| H. Any byproduct material permitted in 10 CFR 35.400 | H. Sealed sources | H. 1 curie total | H. For redistribution of sealed sources initially distributed by a manufacturer licensed in accordance with 10 CFR 32.74 that have been registered either with NRC under 10 CFR 32.210 or with an Agreement State and have been distributed in accordance with an NRC or Agreement State specific license authorizing distribution to persons specifically authorized by an NRC or Agreement State license to receive, possess, and use the authorized device. |
| I. Any byproduct material permitted by 10 CFR 31.11 | I. Prepackaged Kits | I. 20 millicuries total | I. For redistribution to specific licensees or to general licensees in accordance with 10 CFR 31.11, provided the packaging and labeling remain unchanged. |




**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.:
13-32637-01MD

Amendment No. 19

Docket or Reference No.:
030-37428

- | | | | |
|--|--|--|--|
| <p>6. Byproduct, source, and/or special nuclear material</p> <p>J. Germanium-68</p> <p>K. Gallium-68</p> <p>L. Molybdenum-99</p> | <p>7. Chemical and/or physical form</p> <p>J. Any</p> <p>K. Any</p> <p>L. Liquid NorthStar Mo-99/Tc-99m to be used in the RadioGenix® System</p> | <p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>J. 200 millicuries total</p> <p>K. 200 millicuries total</p> <p>L. 19 curies per source vessel, not to exceed 80 curies total</p> | <p>9. Authorized use</p> <p>J. For use of the Eckert and Ziegler GalliaPharm generator for preparation and distribution of radioactive drugs and radiochemicals for medical use in accordance with 10 CFR 32.72 and for non-medical use to authorized recipients.</p> <p>K. Same as Item No. 9.J.</p> <p>L. For use of the NorthStar RadioGenix® System for preparation and distribution of radioactive drugs and radiochemicals for medical use in accordance with 10 CFR 32.72 and for non-medical use to authorized recipients.</p> |
|--|--|--|--|



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.:
13-32637-01MD

Amendment No. 19

Docket or Reference No.:
030-37428

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at 6538 Corporate Dr., Indianapolis, Indiana, 46278

11. The Radiation Safety Officer (RSO) for this license is Brian K. Hardesty, R.Ph.

12. Licensed material shall only be used by, or under the supervision of:

A. A pharmacist working or designated as an authorized nuclear pharmacist in accordance with 10 CFR 32.72(b)(2)(i) or (4).

B. Authorized Nuclear Pharmacists for all licensed material except item No. 6.L.:

Kevin R. Boyd, R.Ph.

Calvin B. Lehman, Pharm.D.

Joseph M. Stamm, R.Ph.

Ishmael Duagbor, Pharm.D.

Yogesh P. Patel, Pharm.D.

Jason J. Wilson, R.Ph.

Shelby R. Koonce, Pharm.D.

Stephen L. Piepenbrink, R.Ph.

C. Authorized Nuclear Pharmacists for all licensed material including Item No. 6.L. for elution of technetium-99m from the NorthStar RadioGenix® System:

Brian K. Hardesty, R.Ph.

James D. Kauchak, R.Ph.

13. A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or by an Agreement State. In the absence of a registration certificate, sealed sources shall be tested for leakage and/or contamination at intervals not to exceed six months, or at such other intervals as specified.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License No.:
13-32637-01MD

Amendment No. 19

Docket or Reference No.:
030-37428

- B. In the absence of a certificate from a transferor indicating that a leak test has been made within the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or by an Agreement State, prior to the transfer, a sealed source received from another person shall not be put into use until tested and the test results received.
- C. Sealed sources need not be tested if they contain only hydrogen-3; or they contain only a radioactive gas; or the half-life of the isotope is 30 days or less; or they contain not more than 100 microcuries of beta- and/or gamma-emitting material or not more than 10 microcuries of alpha-emitting material.
- D. Sealed sources need not be tested if they are in storage and are not being used. However, when they are removed from storage for use or transferred to another person, and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.
- E. The leak test shall be capable of detecting the presence of 185 becquerels (0.005 microcuries) of radioactive material on the test sample. If the test reveals the presence of 185 becquerels (0.005 microcuries) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations.
- F. Tests for leakage and/or contamination shall be performed by the licensee or other persons specifically licensed by the U.S. Nuclear Regulatory Commission or an Agreement State to perform such services. In addition, the licensee is authorized to collect leak test samples for analysis by persons specifically licensed by the Commission or an Agreement State to perform such services.
- G. Records of leak test results shall be kept in units of becquerels (microcuries) and shall be maintained for three years.
14. Sealed sources containing licensed material shall not be opened or sources removed from source holders by the licensee, except as specifically authorized.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License No.:
13-32637-01MD

Amendment No. 19

Docket or Reference No.:
030-37428

15. The licensee shall conduct a physical inventory every six months, or at other intervals approved by the U.S. Nuclear Regulatory Commission, to account for all sealed sources and/or devices received and possessed under the license. Records of inventories shall be maintained for three years from the date of each inventory, and shall include the radionuclides, quantities, manufacturer's name and model numbers, and the date of the inventory.
16. Except for maintaining labeling as required by 10 CFR Part 20, or Part 71, the licensee shall obtain authorization from the U.S. Nuclear Regulatory Commission before making any changes in the sealed source, device, or source-device combination that would alter the description or specifications as indicated in the respective certificate of registration issued either by the U.S. Nuclear Regulatory Commission pursuant to 10 CFR 32.210 or by an Agreement State.
17. The licensee is authorized to hold radioactive material with a physical half-life of less than or equal to 120 days for decay-in-storage before disposal in ordinary trash provided:
- A. Before disposal as ordinary trash, the waste shall be surveyed at the container surface with the appropriate survey instrument set on its most sensitive scale and with no interposed shielding to determine that its radioactivity cannot be distinguished from background. All radiation labels shall be removed or obliterated, except for radiation labels on materials that are within containers and that will be managed as biomedical waste after they have been released from the licensee.
 - B. A record of each such disposal permitted under this license condition shall be retained for three years. The record must include the date of disposal, the date on which the byproduct material was placed in storage, the radionuclides disposed, the survey instrument used, the background dose rate, the dose rate measured at the surface of each waste container, and the name of the individual who performed the disposal.
18. The licensee is authorized to retrieve, receive and dispose of radioactive waste from its customers, limited to radiopharmacy-supplied syringes and vials and their contents.
19. This license does not authorize distribution to persons exempt from licensing.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License No.:
13-32637-01MD

Amendment No. 19

Docket or Reference No.:
030-37428

20. Notwithstanding the requirements of 10 CFR 30.35(a)(1), the licensee is exempt from the requirement to have a decommissioning funding plan needed for the possession and use of germanium-68/gallium-68 medical use generators (Eckert and Ziegler GalliaPharm generators), based on the commitments between the licensee and the manufacturer (Eckert and Ziegler), described in the letter dated June 29, 2017 (ML17191A516).
21. In accordance with letter dated September 27, 2017 (ML17271A040), the licensee may make changes to its radiation safety program, as it relates to the use of germanium-68/gallium-68 generators.
22. The licensee shall not modify the RadioGenix® System from the manufacturer's design and shall only use manufacturer approved consumable replacement parts.
23. The licensee applied for and is authorized to revise its radiation safety program to:
- A. Permit revisions to existing RadioGenix® System radiation safety programs to conform to future changes in licensing guidance and additional safety recommendations from the manufacturer.
 - B. Permit individuals who have received training resulting from safety and operational changes to the RadioGenix® System to use the RadioGenix® System after these changes are made by the manufacturer.
24. The licensee applied for and is authorized to:
- A. Notify the NRC within 30 days when experienced RadioGenix® System Authorized Users and Authorized Nuclear Pharmacists begin working at the facility.
 - B. Notify the NRC within 30 days when a new model of the RadioGenix® System is installed at the facility and ensure training is completed before each individual's first use of the new model.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License No.:
13-32637-01MD

Amendment No. 19

Docket or Reference No.:
030-37428

25. When a new model RadioGenix® System is installed, the licensee shall ensure the following before first use of the new model RadioGenix® System:
- A. Additional training is provided for all authorized individuals, the Radiation Safety Officer, RadioGenix® System Administrator and RadioGenix® System Administrator designee and supervised individuals.
 - B. Individuals must successfully complete the training on the new model prior to their first operation of the system.
 - C. The training is provided by NorthStar or an individual certified by NorthStar to provide the training on the new model of the RadioGenix® System.
 - D. Records of the successful completion of this training are maintained by the licensee for the life of the license for the authorized users, the authorized nuclear pharmacists, and the Radiation Safety Officer, and for three years for all others.
 - E. At a minimum, the record includes the model number of the RadioGenix® System, a list of the topics covered, the date of the instruction, the names of the attendees, and the names of the individuals who provided the instruction. For the authorized users, authorized nuclear pharmacists, and Radiation Safety Officer, the record must also include a written attestation that the individual satisfactorily completed previous training and experience as described in letter dated March 13, 2020 (ML20073J702), Item No. 6, and is able to independently perform the radiation safety related duties of an Authorized User, Authorized Nuclear Pharmacist, or Radiation Safety Officer for the specific model of RadioGenix® System. The written attestation is dated and signed by NorthStar or an individual certified by NorthStar to provide the training and proctor the procedures.


**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License No.:
13-32637-01MD

Amendment No. 19

Docket or Reference No.:
030-37428

26. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated December 29, 2016 (ML17004A159)
- B. Letter dated June 26, 2017 (ML17177A205)
- C. Letter dated June 29, 2017 (ML17191A516)
- D. Letter dated September 27, 2017 (ML17271A040)
- E. Application dated March 18, 2018 (ML18081A845)



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License No.:
13-32637-01MD

Amendment No. 19

Docket or Reference No.:
030-37428

- F. Letter dated June 15, 2018 (ML18169A195)
- G. Letter dated June 19, 2018 (ML18171A056)
- H. Letter dated November 6, 2018 (ML18310A301)
- I. Letter dated March 11, 2020 (ML20073J702)
- J. Letter dated June 8, 2020 (ML20160A434)

Date: June 26, 2024

By: _____

Bryan A. Parker
Region III